, Volume 14, Issue 2, pp 265–271 | Cite as

Gonadotropin releasing hormone analog treatment in children with congenital adrenal hyperplasia complicated by central precocious puberty

  • Ayla Güven
  • Ayşe Nurcan Cebeci
  • Suna Hancili
Research paper



Congenital adrenal hyperplasia (CAH) can be complicated by central precocious puberty (CPP) in children, which may compromise final height. We aimed to evaluate the effect of gonadotropin-releasing hormone analog (GnRHa) therapy on growth in children with CAH.


Twelve children with CAH were enrolled in a follow-up study. Eight patients underwent the GnRH stimulation test. GnRHa-treatment was administered at 3.75 mg every 4 weeks; the dose had to be increased to 7.5 mg in three patients. Bone age, growth velocities and body mass index of the patients were monitored during treatment.


Median chronologic age and bone age at diagnosis were 6.8 (3.5) years and 11 (1.2) years, respectively. Median follow-up was 4.4 (4.9) years. A significant difference was found in the median ratio of bone age to chronological age between diagnosis and last visit (p=0.005) and between the beginning of GnRHa treatment and last visit (p=0.004). Median growth velocity was 4 (2.5) cm, 3.4 (5.2) cm and 5.5 (5.5) cm at the end of the first, second and third years of the therapy, respectively. Second-year growth velocity was inversely correlated with median bone age at diagnosis (rho:−0.758, p=0.004) and at the initiation of therapy (rho:−0.876, p<0.001).


GnRHa therapy should be considered for augmentation of linear growth and diminishment of bone age advancement in children with CAH complicated by CPP, particularly in children who do not have extremely advanced bone age for chronological age.

Key words

Childhood Congenital adrenal hyperplasia Leuprolide acetate Precocious puberty 


  1. 1.
    White PC, Speiser PW, 2000 Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 21: 245–291.Google Scholar
  2. 2.
    Lim YJ, Batch JA, Warne GL, 1995 Adrenal 21-hydroxylase deficiency in childhood: 25 years’ experience. J Paediatr Child Health 31: 222–227.CrossRefGoogle Scholar
  3. 3.
    Jääskeläinen J, Voutilainen R, 1997 Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height. Pediatr Res 41: 30–33.CrossRefGoogle Scholar
  4. 4.
    Pescovitz OH, Cassorla F, Comite F, Loriaux DL, Cutler GB Jr, 1985 LHRH analog treatment of central precocious puberty complicating congenital adrenal hyperplasia. Ann N Y Acad Sci 458: 174–181.CrossRefGoogle Scholar
  5. 5.
    Dacou-Voutetakis C, Karidis N, 1993 Congenital adrenal hyperplasia complicated by central precocious puberty: treatment with LHRH-agonist analogue. Ann N Y Acad Sci 687: 250–254.CrossRefGoogle Scholar
  6. 6.
    Soliman AT, Al Lamki M, Al Salmi I, Asfour M, 1997 Congenital adrenal hyperplasia complicated by central precocious puberty: linear growth during infancy and treatment with gonadotropin-releasing hormone analog. Metabolism 46: 513–517.CrossRefGoogle Scholar
  7. 7.
    Partsch CJ, Heger S, Sippell WG, 2002 Management and outcome of central precocious puberty. Clin Endocrin 56: 129–148.CrossRefGoogle Scholar
  8. 8.
    Neyzi O, Furman A, Bundak R, Gunoz H, Darendeliler F, Bas F, 2006 Growth references for Turkish children aged 6 to 18 years. Acta Paediatr 95: 1635–1641.CrossRefGoogle Scholar
  9. 9.
    Marshall WA, Tanner JM, 1969 Variations in pattern of pubertal changes in girls. Arch Dis Child 44: 291–303.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Marshall WA, Tanner JM, 1970 Variations in the pattern of pubertal changes in boys. Arch Dis Child 45: 13–23.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Greulich WW, Pyle SI 1959 Radiographic atlas of skeletal development of the hand and wrist. Stanford University Press, Palo Alto.Google Scholar
  12. 12.
    Bayley N, Pinneau S, 1952 Tables for predicting adult height from skeletal age: revised for use with Greulich-Pyle hand standards. J Pediatr 40: 423–441.CrossRefGoogle Scholar
  13. 13.
    Bonfig W, Schwarz HP, 2012 Overestimation of final height prediction in patients with classical congenital adrenal hyperplasia using the Bayley and Pinneau method. J Pediatr Endocrinol Met 25: 645–649.Google Scholar
  14. 14.
    Carel JC, Lahlou N, Roger M, Chaussain JL, 2004 Precocious puberty and statural growth. Hum Reprod Update 10: 135–147.CrossRefGoogle Scholar
  15. 15.
    Badouraki M, Christoforidis A, Economou I, Dimitriadis AS, Katzos G, 2008 Evaluation of pelvic ultrasonography in the diagnosis and differentiation of various forms of sexual precocity in girls. Ultrasound Obstet Gynecol 32: 819–827.CrossRefGoogle Scholar
  16. 16.
    Demirbilek H, Alikasifoglu A, Gonc NE, Ozon A, Kandemir N, 2012 Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection. Clin Endocrinol (Oxf) 76: 126–130.CrossRefGoogle Scholar
  17. 17.
    Pucarelli I, Segni M, Ortore M, Arcadi E, Pasquino AM, 2003 Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution. J Pediatr Endocrinol Metab 16: 1005–1010.CrossRefGoogle Scholar
  18. 18.
    Lin-Su K, Vogiatzi MG, Marshall I, et al, 2005 Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 90: 3318–3325.CrossRefGoogle Scholar
  19. 19.
    Lin-Su K, Harbison MD, Lekarev O, New MI, 2001 Final adult height in children with congenital adrenal hyperplasia treated with growth hormone. Clin Endocrinol Metab 96: 1710–1717.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2015

Authors and Affiliations

  • Ayla Güven
    • 1
  • Ayşe Nurcan Cebeci
    • 1
  • Suna Hancili
    • 1
  1. 1.Çocuk Endokrin KlinigiGöztepe Eğitim ve Araştirma HastanesiIstanbulTürkiye

Personalised recommendations